News coverage about Oxford Immunotec Global PLC (NASDAQ:OXFD) has trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oxford Immunotec Global PLC earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.4815762237406 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Head to Head Analysis: Oxford Immunotec Global PLC (OXFD) and Varex Imaging (VREX) (americanbankingnews.com)
- BRIEF-Oxford Immunotec updates on amendment to supply agreement with StemCell Technologies (feeds.reuters.com)
- Director of Oxford Immunotec Global Plc (NASDAQ:OXFD), Sandberg Richard A, sells 3,000 shares worth $47,460 (empowerednews.net)
- Oxford Immunotec Global PLC (OXFD) Director Sells $47,460.00 in Stock (americanbankingnews.com)
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, August 30th. Piper Jaffray Companies restated a “buy” rating and set a $26.00 price target on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. ValuEngine upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cowen and Company dropped their price target on Oxford Immunotec Global PLC from $22.00 to $19.00 and set an “outperform” rating on the stock in a research note on Thursday, August 17th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Oxford Immunotec Global PLC currently has a consensus rating of “Hold” and an average price target of $20.25.
Shares of Oxford Immunotec Global PLC (OXFD) traded down 0.95% during midday trading on Tuesday, reaching $15.58. The company had a trading volume of 74,177 shares. The company’s 50 day moving average price is $16.26 and its 200 day moving average price is $15.46. Oxford Immunotec Global PLC has a 52-week low of $10.86 and a 52-week high of $19.51. The stock’s market capitalization is $359.52 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.32). The firm had revenue of $26.10 million for the quarter, compared to the consensus estimate of $25.05 million. Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The firm’s quarterly revenue was up 35.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.29) EPS. Equities research analysts expect that Oxford Immunotec Global PLC will post ($1.63) earnings per share for the current year.
In other Oxford Immunotec Global PLC news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $15.82, for a total value of $47,460.00. Following the transaction, the director now directly owns 18,000 shares in the company, valued at approximately $284,760. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Elizabeth M. Keiley sold 4,085 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $15.01, for a total value of $61,315.85. Following the completion of the transaction, the vice president now owns 25,393 shares in the company, valued at $381,148.93. The disclosure for this sale can be found here. Insiders sold a total of 129,195 shares of company stock worth $2,121,142 over the last quarter. Company insiders own 7.58% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Oxford Immunotec Global PLC (OXFD) Receiving Somewhat Positive News Coverage, Accern Reports” was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thestockobserver.com/2017/09/12/oxford-immunotec-global-plc-oxfd-receiving-somewhat-positive-news-coverage-accern-reports.html.
Oxford Immunotec Global PLC Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.